Antibody as a drug modality contributes to the first runner of biomedicine. Recently, research and development of next generation antibody drugs has remarkable progresses on therapy, e.g. antibody drug conjugate (ADC), bispecific antibody (bsAb), and single domain antibody (VHH, also called nanobody), which has widen the application areas of antibody drugs. These include combination of elemental technologies, and incorporation of information sciences into the drug development. Here I would discuss next generation drug modality, especially focusing on innovation-driven antibody engineering.